Stock-Based Compensation |
6 Months Ended | ||
|---|---|---|---|
Jun. 30, 2026 | |||
| Share-Based Payment Arrangement [Abstract] | |||
| Stock-Based Compensation |
2026 Equity Incentive Plan
On May 31, 2026, the Company’s Board of Directors adopted the Curanex Pharmaceuticals Inc 2026 Equity Incentive Plan (the “2026 Plan”), which was approved by the Company’s stockholders on June 11, 2026. The 2026 Plan permits the grant of stock options, restricted stock, restricted stock units and other stock-based awards to employees, directors and consultants of the Company. An aggregate of shares of common stock, par value $ per share, are reserved and available for issuance under the 2026 Plan, representing approximately 20.1% of the shares of common stock issued and outstanding as of June 30, 2026. The 2026 Plan is administered by the Board of Directors, or a committee designated by the Board, which determines the recipients, types, terms, vesting conditions and, where applicable, exercise prices of awards. The number of shares reserved under the 2026 Plan is subject to proportionate adjustment in the event of a stock split, reverse stock split, stock dividend, recapitalization or similar change in the Company’s capitalization.
On July 21, 2026, the Company filed a Registration Statement on Form S-8 with the Securities and Exchange Commission registering of the shares of common stock reserved for issuance under the 2026 Plan, representing approximately 10.58% of the shares of common stock issued and outstanding as of the date of filing. The Registration Statement became effective upon filing in accordance with Rule 462 under the Securities Act of 1933, as amended. The remaining shares reserved under the 2026 Plan have not been registered.
awards were granted under the 2026 Plan during the three and six months ended June 30, 2026, and shares of common stock had been issued under the 2026 Plan as of June 30, 2026. Accordingly, compensation cost related to the 2026 Plan was recognized for the three and six months ended June 30, 2026, and there was unrecognized compensation cost related to the 2026 Plan as of June 30, 2026.
Other Stock-Based Compensation
On March 18, 2026, the Company issued an aggregate of shares of common stock to Dr. Huijuan Zhong as additional compensation pursuant to an employment arrangement entered into in June 2024 (see Note 7, Shareholders’ Equity). Following the Company’s initial public offering, the Company issued the full shares in a single issuance, and no further service-based forfeiture conditions remained after issuance. All shares were vested upon issuance. The shares were valued at $ per share, the closing price of the Company’s common stock on March 17, 2026 as reported on Nasdaq. The Company recognized stock-based compensation expense of $ and $ within general and administrative expenses for the three and six months ended June 30, 2026, respectively, and $ for the three and six months ended June 30, 2025. |